Gut Microbiome AI Diagnostic Platform GutMind: Predicting the Risk of 50 Diseases Through Gut Bacteria

Gut Microbiome AI Diagnostic Platform GutMind: Predicting the Risk of 50 Diseases Through Gut Bacteria

Israeli microbiome technology company DayTwo today officially launched the GutMind gut microbiome AI diagnostic platform. The platform analyzes users' gut microbiota metagenomic sequencing data to predict the risk of 50 common diseases over the next 5 years.

GutMind's workflow is straightforward: users collect a stool sample and mail it to DayTwo's laboratory, then view a complete health risk assessment report in a mobile app 7 days later. The platform is built on a training set containing gut microbiome data from 1.2 million people, covering a broad predictive range from metabolic diseases to neuropsychiatric disorders.

In validation studies, GutMind achieved a 5-year prediction accuracy of 87.3% for type 2 diabetes, 85.1% for major depressive disorder, and 89.2% for inflammatory bowel disease. All of these metrics significantly exceed traditional prediction models based on age, BMI, and family history.

DayTwo CEO Mariam Eliat said: "The gut is the body's largest endocrine organ, and changes in gut microbiota often reflect disease risk earlier than blood markers. GutMind enables ordinary people to access microbiome analysis through a single stool sample that previously was only available at top-tier hospitals."

On the scientific foundation, GutMind's AI model is built on the explosion of gut-brain axis research in recent years. Gut microbiota communicate bidirectionally with the brain through three pathways: the vagus nerve, the immune system, and metabolic products. Imbalances in specific microbiota are associated with neurological conditions including Parkinson's disease, Alzheimer's disease, and autism.

For clinical application scenarios, GutMind currently targets three user groups: first, high-risk individuals with family medical histories for early warning; second, chronic disease patients for monitoring treatment effectiveness; and third, health management enthusiasts for optimizing diet and lifestyle.

On privacy protection, users' microbiome data is stored with end-to-end encryption, and DayTwo promises not to sell personal data to third parties. Users can request deletion of all data at any time.

Professor Curtis Huttenhower, Director of the Microbiome Research Center at Harvard's T.H. Chan School of Public Health, commented: "Microbiome diagnostics is the next frontier of precision medicine. GutMind's scaled validation data is impressive, but more longitudinal studies are needed to confirm causal relationships."

GutMind is priced at $299 per test and is currently available in the United States, EU, and Israel, with plans to enter the Asian market in 2031.